and Nuclear Medicine, St. Petersburg, Russian Federation 1 , S.V. Kanaev 1 Purpose or Objective: to analyze possible clinical value of lymph flow visualization as the guide for irradiation of IMLN.
Purpose or Objective: To assess the feasibility of Simultaneous Integrated Boost in Intensity Modulated Radiotherapy (SIB-IMRT) for breast cancer (BC) in the attempt to reduce the radiation treatment time. Results in terms of late toxicity and local control were compared with a control group (CG) of patients treated with 3-dimensional (3-D) conformal radiotherapy plus sequential boost.
Material and Methods:
MARA-2 was conceived as a single arm phase I-II trial. Patients with moderate-high risk BC were enrolled and treated with forward-planned IMRT technique. Whole breast and tumor bed received a total dose of 50 Gy and 60 Gy (10 Gy concomitant boost) in 25 daily fractions, respectively. In CG group, prescribed dose to the breast was 50.4 Gy in 28 fractions with a sequential 10 Gy boost to the tumor bed in 4 fractions. Late skin and subcutaneous toxicity were evaluated using EORTC/RTOG scoring scale.
Results:
Four hundred and fifty one patients were included in our study (MARA-2: 321; CG: 130). Median follow up was 52 months (range: 3-115). G1 and G2 late skin toxicities were acceptable without significant differences between the two groups. No G≥3 late skin toxicity was observed in MARA-2. At univariate analysis, late G1 and G2 subcutaneous toxicities were significantly higher in MARA-2 (p<0.001). 5-year G1 subcutaneous late toxicity free-survival (LTFS) were 73.4% and 38.5% in CG and MARA-2, respectively; moreover, 5-year G2 subcutaneous LTFS were 96.5% and 80.0% in CG and MARA-2, respectively. 5-year G3 subcutaneous LTFS was 0.9% in MARA-2 and 0% in CG, respectively. No differences were found in term of loco-regional control (LC) with a 5-LC of 96.7% and 97.6% in CG and MARA-2, respectively (p=0.676).
Conclusion:
The use of SIB-IMRT technique in postoperative radiotherapy of BC allowed to reduce overall treatment time without significantly increasing the incidence of G>2 late effects.
EP-1153
Hypofractionated radiotherapy and simultaneous boost in breast cancer: preliminary result in elderly N. Giaj-Levra 1 Ospedale Sacro Cuore -Don Calabria, Radiation Oncology, Negrar -Verona, Italy 1 , A. Fiorentino 1 , R. Mazzola 1 , S. Fersino 1 , F. Ricchetti 1 , G. Sicignano 1 , S. Naccarato 1 , R. Ruggieri 1 , F. Alongi 1 Purpose or Objective: To evaluate the feasibility and toxicity profile in elderly women, with a diagnosis of early stage breast cancer, underwent to adjuvant hypofractionated Volumetric Modulated Arc Therapy (VMAT) and simultaneous integrated boost (SIB) after conserving surgery (CS).
Material and Methods:
Between September 2013 to March 2015, 50 consecutive women with a diagnosis of early stage of breast cancer were treated with SIB-VMAT after CS in our Institution. Inclusion criteria were: age ≥ 65 years, pT1 -2 disease, pN 0-1, no neoadjuvant chemotherapy, nometastatic disease. A dose prescription of 40.5 Gy in 15 fractions was prescribed to the whole breast (PTVbreast) and an additional radiation dose of 48.5 Gy in 15 fractions to the tumour bed was prescribed (PTVboost). Hypofractionated treatment was purposed in patients with negative margins after surgery (> 1 mm). All patients were followed with periodic clinical evaluation. Acute toxicity were scored using EORTC/RTOG radiation morbidity score system. Both patient and physician recorded cosmetic outcome evaluation with a subjective judgment scale at the time of scheduled followup.
Results: Median follow-up was 20 months. At the time of the analysis, overall survival and local control rates were 100%. All patients completed the SIB-VMAT without interruptions. Acute skin toxicity was recorded as follow: grade 0 in 22 patients (44%), grade 1 in 24 cases (48%), grade 2 in 4 patients (8%). Regarding late adverse events, skin toxicity was registered as follow: grade 0 in 40 patients (80%), grade 1 in 10 cases (20%). No toxicity ≥ grade 2 was registered. In
